SE7900458L
(sv)
*
|
1978-01-27 |
1979-07-28 |
Sandoz Ag |
Liposom-avgivningssystem for lekemedel
|
GB2026340B
(en)
*
|
1978-07-03 |
1982-12-22 |
Ash P |
Stabilising microvesicles
|
JPS56120612A
(en)
*
|
1980-02-27 |
1981-09-22 |
Kanebo Keshohin Kk |
Beautifying cosmetic
|
US4820811A
(en)
*
|
1982-04-21 |
1989-04-11 |
Research Corporation |
Amine reacted therapeutic agents
|
US4451647A
(en)
*
|
1982-06-21 |
1984-05-29 |
Research Corporation |
Heparinized polyorganophosphazenes
|
US4542019A
(en)
*
|
1983-03-11 |
1985-09-17 |
John Lezdey |
Antacid compositions
|
DE3331009A1
(de)
*
|
1983-08-27 |
1985-03-14 |
Basf Ag, 6700 Ludwigshafen |
Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
|
JPS60208910A
(ja)
*
|
1984-03-31 |
1985-10-21 |
Green Cross Corp:The |
水難溶性薬物・リン脂質複合体の製造方法
|
FR2568774B2
(fr)
*
|
1984-05-30 |
1989-05-19 |
Choay Sa |
Medicaments favorisant les proprietes d'ecoulement du sang et leur utilisation en therapeutique
|
FR2584728B1
(fr)
*
|
1985-07-12 |
1987-11-20 |
Choay Sa |
Procede de sulfatation de glycosaminoglycanes et de leurs fragments
|
US4923854A
(en)
*
|
1986-01-22 |
1990-05-08 |
The Liposome Company, Inc. |
Solubilization of hydrophobic materials using lysophospholipid
|
DE3614657A1
(de)
*
|
1986-04-30 |
1987-11-05 |
Dornier Medizintechnik |
Pharmaka enthaltende lipidvesikel, verfahren zu ihrer herstellung und einbringung in den koerper eines lebewesens und freisetzung der in den lipidvesikeln enthaltende pharmaka
|
US4745107A
(en)
*
|
1986-08-20 |
1988-05-17 |
Foley Kevin M |
Heparin derivatives with improved permeability
|
US4745105A
(en)
*
|
1986-08-20 |
1988-05-17 |
Griffin Charles C |
Low molecular weight heparin derivatives with improved permeability
|
US4925678A
(en)
*
|
1987-04-01 |
1990-05-15 |
Ranney David F |
Endothelial envelopment drug carriers
|
US4916117A
(en)
*
|
1986-12-24 |
1990-04-10 |
John Lezdey |
Treatment of inflammation using alpha 1-antichymotrypsin
|
US5008242A
(en)
*
|
1986-12-24 |
1991-04-16 |
John Lezdey |
Treatment of inflammation using 1-antichymotrypsin
|
US4879282A
(en)
*
|
1987-03-17 |
1989-11-07 |
Saliba Jr Michael J |
Medical application for heparin and related molecules
|
US4938965A
(en)
*
|
1987-07-22 |
1990-07-03 |
Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government |
Ocular delivery of prophylactic agents
|
US5733892A
(en)
*
|
1990-07-24 |
1998-03-31 |
Seikagaku Corporation |
Metastasis inhibitor composition comprising a phospholipid-linked glycosaminoglycan and method for inhibiting metastasis employing the same
|
US5464942A
(en)
*
|
1990-07-24 |
1995-11-07 |
Seikagaku Kogyo Kabushiki Kaisha |
Phospholipid- or lipid-linked glycosaminoglycan and process for producing the same
|
US6099856A
(en)
*
|
1992-06-15 |
2000-08-08 |
Emisphere Technologies, Inc. |
Active agent transport systems
|
US5693338A
(en)
*
|
1994-09-29 |
1997-12-02 |
Emisphere Technologies, Inc. |
Diketopiperazine-based delivery systems
|
US5578323A
(en)
|
1992-06-15 |
1996-11-26 |
Emisphere Technologies, Inc. |
Proteinoid carriers and methods for preparation and use thereof
|
US6221367B1
(en)
|
1992-06-15 |
2001-04-24 |
Emisphere Technologies, Inc. |
Active agent transport systems
|
US5714167A
(en)
*
|
1992-06-15 |
1998-02-03 |
Emisphere Technologies, Inc. |
Active agent transport systems
|
AR244546A1
(es)
*
|
1990-10-30 |
1993-11-30 |
Gador Y Cia S A C I Lab Dr |
Procedimiento para la preparacion de liposomas de drogas insolubles en aceite en capsulas blandas de gelatina enterosolubles.
|
JP3199405B2
(ja)
*
|
1991-08-30 |
2001-08-20 |
生化学工業株式会社 |
肝細胞球状集塊化剤及び球状集塊化肝細胞の製造方法
|
FR2685868B1
(fr)
*
|
1992-01-03 |
1995-06-23 |
Corbiere Jerome |
Nouvelles preparations pharmaceutiques a base de peptides pour la voie generale.
|
WO1995001163A1
(fr)
*
|
1992-01-03 |
1995-01-12 |
Corbiere Jerome |
Nouvelles preparations pharmaceutiques a base de peptides pour la voie generale
|
US6916489B2
(en)
*
|
1992-06-15 |
2005-07-12 |
Emisphere Technologies, Inc. |
Active agent transport systems
|
US5342621A
(en)
*
|
1992-09-15 |
1994-08-30 |
Advanced Cardiovascular Systems, Inc. |
Antithrombogenic surface
|
US5643957A
(en)
*
|
1993-04-22 |
1997-07-01 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US20010003001A1
(en)
|
1993-04-22 |
2001-06-07 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US6610329B2
(en)
|
1993-04-22 |
2003-08-26 |
Emisphere Technologies Inc. |
Compositions for the delivery of antigens
|
DE4313402A1
(de)
*
|
1993-04-23 |
1994-10-27 |
Hexal Pharma Gmbh |
Transdermale Wirkstoffzubereitung
|
WO1994026251A1
(en)
*
|
1993-05-07 |
1994-11-24 |
Sequus Pharmaceuticals, Inc. |
Subcutaneous liposome delivery method
|
WO1997036480A1
(en)
|
1996-03-29 |
1997-10-09 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US6001347A
(en)
|
1995-03-31 |
1999-12-14 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
BR9604880A
(pt)
*
|
1995-03-31 |
1998-05-19 |
Emisphere Tech Inc |
Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
|
US6090958A
(en)
*
|
1995-03-31 |
2000-07-18 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5989539A
(en)
*
|
1995-03-31 |
1999-11-23 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5750147A
(en)
|
1995-06-07 |
1998-05-12 |
Emisphere Technologies, Inc. |
Method of solubilizing and encapsulating itraconazole
|
US6106866A
(en)
*
|
1995-07-31 |
2000-08-22 |
Access Pharmaceuticals, Inc. |
In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
|
DE19681560T1
(de)
*
|
1995-09-11 |
1998-08-20 |
Emisphere Tech Inc |
Verfahren zur Herstellung von omega-Aminoalkansäure-Derivaten aus Cycloalkanonen
|
EP0904065A4
(en)
|
1996-06-14 |
2000-06-14 |
Emisphere Tech Inc |
MICRO-ENCLOSED FRAGRANCES AND PRODUCTION METHOD
|
IE960485A1
(en)
*
|
1996-07-02 |
1998-01-14 |
Univ Dublin |
Organised assemblies containing entrapped negatively charged¹polyelectrolytes
|
WO1998021951A1
(en)
|
1996-11-18 |
1998-05-28 |
Emisphere Technologies, Inc. |
Methods and compositions for inducing oral tolerance in mammals
|
US5804688A
(en)
*
|
1997-02-07 |
1998-09-08 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US6358504B1
(en)
|
1997-02-07 |
2002-03-19 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5990166A
(en)
*
|
1997-02-07 |
1999-11-23 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US6060513A
(en)
*
|
1997-02-07 |
2000-05-09 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
CA2319672C
(en)
|
1997-02-07 |
2011-01-04 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5773647A
(en)
*
|
1997-02-07 |
1998-06-30 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US6313088B1
(en)
|
1997-02-07 |
2001-11-06 |
Emisphere Technologies, Inc. |
8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
|
US5863944A
(en)
*
|
1997-04-30 |
1999-01-26 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5962710A
(en)
*
|
1997-05-09 |
1999-10-05 |
Emisphere Technologies, Inc. |
Method of preparing salicyloylamino acids
|
ATE267613T1
(de)
*
|
1998-03-05 |
2004-06-15 |
Phares Pharm Res Nv |
Arzneimittel und deren verwendung
|
KR100314496B1
(ko)
|
1998-05-28 |
2001-11-22 |
윤동진 |
항혈전성이 있는 헤파린 유도체, 그의 제조방법 및 용도
|
US6761903B2
(en)
|
1999-06-30 |
2004-07-13 |
Lipocine, Inc. |
Clear oil-containing pharmaceutical compositions containing a therapeutic agent
|
ES2235854T3
(es)
*
|
1999-04-05 |
2005-07-16 |
Emisphere Technologies, Inc. |
Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
|
US6458383B2
(en)
|
1999-08-17 |
2002-10-01 |
Lipocine, Inc. |
Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
|
US6982281B1
(en)
*
|
2000-11-17 |
2006-01-03 |
Lipocine Inc |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
US6908900B2
(en)
*
|
2001-01-17 |
2005-06-21 |
Zimmer & Associates Ag |
Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients
|
US7671029B2
(en)
|
1999-08-06 |
2010-03-02 |
Immupharma Sa |
Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances
|
US20030060413A1
(en)
*
|
2001-09-06 |
2003-03-27 |
Zimmer Robert H. |
Derivatives of pseudo-peptides, their preparation and their biological uses
|
US7129274B1
(en)
|
1999-11-05 |
2006-10-31 |
Emisphere Technologies Inc. |
Phenoxy carboxylic acid compounds and compositions for delivering active agents
|
US7279597B1
(en)
|
1999-11-05 |
2007-10-09 |
Emisphere Technologies, Inc. |
Phenyl amine carboxylic acid compounds and compositions for delivering active agents
|
US6251136B1
(en)
|
1999-12-08 |
2001-06-26 |
Advanced Cardiovascular Systems, Inc. |
Method of layering a three-coated stent using pharmacological and polymeric agents
|
ATE387430T1
(de)
|
1999-12-16 |
2008-03-15 |
Emisphere Tech Inc |
Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
|
US6489311B1
(en)
*
|
2000-05-02 |
2002-12-03 |
Charlotte-Mecklenburg Hospital Authoirty |
Method for the prevention of apoptosis
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
EP1406571A4
(en)
*
|
2001-06-25 |
2007-05-30 |
Depuy Int Ltd |
LIPOSOMAL ENCAPSULATION OF GLYCOSAMINOGLYCANS FOR THE TREATMENT OF ARTHROSIS JOINTS
|
CA2451248A1
(en)
*
|
2001-06-25 |
2003-01-03 |
Depuy International Limited |
Composition comprising glycosaminoglycans and hyaluronidase inhibitors for the treatment of arthritic joints
|
IL161968A0
(en)
|
2001-11-14 |
2005-11-20 |
Centocor Inc |
Anti-il-6 antibodies, compositions, methods and uses
|
US20030180348A1
(en)
*
|
2002-03-22 |
2003-09-25 |
Levinson R. Saul |
Transcellular drug delivery system
|
US20040072796A1
(en)
*
|
2002-04-18 |
2004-04-15 |
Embury Stephen H. |
Method and composition for preventing pain in sickle cell patients
|
JP2006504406A
(ja)
|
2002-06-28 |
2006-02-09 |
セントカー・インコーポレーテツド |
哺乳動物のch1欠失ミメティボディ、組成物、方法および使用
|
US6702850B1
(en)
|
2002-09-30 |
2004-03-09 |
Mediplex Corporation Korea |
Multi-coated drug-eluting stent for antithrombosis and antirestenosis
|
WO2004043140A2
(en)
*
|
2002-11-07 |
2004-05-27 |
Advanced Bionutrition Corp. |
Nutraceuticals and method of feeding aquatic animals
|
AU2004239288B2
(en)
|
2003-05-09 |
2010-01-28 |
Centocor, Inc. |
IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
|
WO2005019184A1
(en)
|
2003-08-20 |
2005-03-03 |
Eli Lilly And Company |
Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
|
CA2530983C
(en)
*
|
2003-08-20 |
2012-09-25 |
Eli Lilly And Company |
Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
|
UA89481C2
(uk)
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
JP2005209106A
(ja)
*
|
2004-01-26 |
2005-08-04 |
Nec Corp |
携帯通信端末、受信メール管理方法、プログラムおよび記録媒体
|
US7252446B2
(en)
*
|
2004-03-31 |
2007-08-07 |
Brother Kogoy Kabushiki Kaisha |
Image forming apparatus
|
EA011583B1
(ru)
*
|
2004-03-31 |
2009-04-28 |
Сентокор, Инк. |
Миметические антитела glp-1 человека, композиции, способы и применения
|
US7393662B2
(en)
*
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
PA8672101A1
(es)
|
2005-04-29 |
2006-12-07 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, métodos y usos
|
EP3501537A1
(en)
|
2005-06-30 |
2019-06-26 |
Janssen Biotech, Inc. |
Anti-il23 antibodies, compositions, methods and uses
|
MX2008000974A
(es)
*
|
2005-07-22 |
2008-03-27 |
Univ California |
Composiciones de heparina e inhibicion de selectina.
|
PL1971366T3
(pl)
|
2005-12-29 |
2015-01-30 |
Janssen Biotech Inc |
Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie
|
EP2007602A4
(en)
*
|
2006-03-31 |
2010-09-22 |
Centocor Ortho Biotech Inc |
HUMAN EPO MIMETICS IN HINGED CENTRAL REGION, COMPOSITIONS, METHODS AND USES IN THE PREVENTION OR TREATMENT OF GLUCOSE INTOLERANCE OR ANEMIA ASSOCIATED WITH NEPHROPATHY
|
TW200843794A
(en)
*
|
2006-12-21 |
2008-11-16 |
Centocor Inc |
Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
|
US20100021538A1
(en)
*
|
2008-02-29 |
2010-01-28 |
Youngro Byun |
Pharmaceutical compositions containing heparin derivatives
|
MX2011001409A
(es)
|
2008-08-14 |
2011-03-29 |
Cephalon Australia Pty Ltd |
Anticuerpos anti-il-12/il-23.
|
RS55218B1
(sr)
|
2008-10-31 |
2017-02-28 |
Janssen Biotech Inc |
Kompozicije fibronektin tip iii skalno baziranih domena, metode i upotrebe
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
JP5873335B2
(ja)
|
2009-02-12 |
2016-03-01 |
ヤンセン バイオテツク,インコーポレーテツド |
フィブロネクチンiii型ドメインに基づくスカフォールド組成物、方法及び使用
|
DK3323830T3
(da)
|
2010-06-19 |
2023-09-25 |
Memorial Sloan Kettering Cancer Center |
Anti-gd2 antibodies
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9358241B2
(en)
|
2010-11-30 |
2016-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9034858B2
(en)
|
2010-11-30 |
2015-05-19 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
JP2015509499A
(ja)
|
2012-02-21 |
2015-03-30 |
アドバンスド バイオニュートリション コーポレイション |
水生生物に生物活性剤をターゲット送達するための組成物および方法
|
HUE053247T2
(hu)
|
2012-05-09 |
2021-06-28 |
Cantex Pharmaceuticals Inc |
Mieloszuppresszió kezelése
|
US20140255403A1
(en)
|
2013-03-06 |
2014-09-11 |
Hadasit Medical Research Services & Development Ltd. |
Oral composition comprising a tnf antagonist and use thereof
|
US8962836B2
(en)
|
2013-03-15 |
2015-02-24 |
Mannkind Corporation |
Formation of N-protected bis-3,6-(4-aminobutyl)-2,5-diketopiperazine through a cyclic alpha-N-protected amino ester
|
CA2903576C
(en)
|
2013-03-15 |
2021-06-08 |
Nai-Kong V. Cheung |
High affinity anti-gd2 antibodies
|
WO2016033556A1
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
|
US20170246187A1
(en)
|
2014-08-28 |
2017-08-31 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
US10052346B2
(en)
|
2015-02-17 |
2018-08-21 |
Cantex Pharmaceuticals, Inc. |
Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
|
CN107667120B
(zh)
|
2015-03-17 |
2022-03-08 |
纪念斯隆-凯特林癌症中心 |
抗muc16抗体及其应用
|
US20190177421A1
(en)
|
2016-07-15 |
2019-06-13 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors and methods for use
|
WO2018014039A1
(en)
|
2016-07-15 |
2018-01-18 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors (cars) specific for muc1 and methods for their use
|
JP6409837B2
(ja)
*
|
2016-09-08 |
2018-10-24 |
トヨタ自動車株式会社 |
回転電機ロータ及び回転電機ロータの製造方法
|
CA3078723A1
(en)
|
2016-11-28 |
2018-05-31 |
Nachiappan Chidambaram |
Oral testosterone undecanoate therapy
|
EP3574012A1
(en)
|
2017-01-27 |
2019-12-04 |
Memorial Sloan Kettering Cancer Center |
Bispecific her2 and cd3 binding molecules
|
EP3573658A4
(en)
|
2017-01-30 |
2021-07-21 |
Janssen Biotech, Inc. |
ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
|
JP2020506947A
(ja)
|
2017-02-07 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法
|
MX2020006689A
(es)
|
2017-12-20 |
2020-11-06 |
Poseida Therapeutics Inc |
Composiciones de vcar y metodos de uso.
|
JP2021523138A
(ja)
|
2018-05-11 |
2021-09-02 |
ヤンセン バイオテツク,インコーポレーテツド |
Il−23抗体を使用してうつを治療する方法
|
US20220042038A1
(en)
|
2018-12-20 |
2022-02-10 |
Poseida Therapeutics, Inc. |
Nanotransposon compositions and methods of use
|
WO2020148651A1
(en)
|
2019-01-15 |
2020-07-23 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
US20220064278A1
(en)
|
2019-01-23 |
2022-03-03 |
Janssen Biotech, Inc. |
Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis
|
MA55282A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
|
EP3938391A1
(en)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
EA202192508A1
(ru)
|
2019-03-14 |
2022-03-29 |
Янссен Байотек, Инк. |
Способы получения композиций антитела к фно
|
CN113874073A
(zh)
|
2019-05-23 |
2021-12-31 |
詹森生物科技公司 |
用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
|
JP2022535534A
(ja)
|
2019-06-03 |
2022-08-09 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法
|
EP3976648A1
(en)
|
2019-06-03 |
2022-04-06 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
AU2020342544A1
(en)
|
2019-09-05 |
2022-03-24 |
Poseida Therapeutics, Inc. |
Allogeneic cell compositions and methods of use
|
WO2021127505A1
(en)
|
2019-12-20 |
2021-06-24 |
Poseida Therapeutics, Inc. |
Anti-muc1 compositions and methods of use
|
AU2021230361A1
(en)
|
2020-03-04 |
2022-09-08 |
Poseida Therapeutics, Inc. |
Compositions and methods for the treatment of Metabolic Liver Disorders
|
WO2021183795A1
(en)
|
2020-03-11 |
2021-09-16 |
Poseida Therapeutics, Inc. |
Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
|
MX2022012956A
(es)
|
2020-04-14 |
2023-03-27 |
Poseida Therapeutics Inc |
Composiciones y métodos para su uso en el tratamiento del cáncer.
|
WO2021214588A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating coronavirus infections
|
WO2021214587A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating viral infections
|
EP4298205A1
(en)
|
2021-02-23 |
2024-01-03 |
Poseida Therapeutics, Inc. |
Genetically modified induced pluripotent stem cells and methods of use thereof
|
EP4301863A1
(en)
|
2021-03-04 |
2024-01-10 |
Poseida Therapeutics, Inc. |
Compositions and methods for the treatment of hemophilia
|
EP4367137A1
(en)
|
2021-07-09 |
2024-05-15 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
KR20240034218A
(ko)
|
2021-07-09 |
2024-03-13 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물을 생산하기 위한 제조 방법
|
CA3233506A1
(en)
|
2021-10-04 |
2023-04-13 |
Joseph S. LUCAS |
Transposon compositions and methods of use thereof
|
WO2023164573A1
(en)
|
2022-02-23 |
2023-08-31 |
Poseida Therapeutics, Inc. |
Genetically modified cells and methods of use thereof
|
WO2024036273A1
(en)
|
2022-08-11 |
2024-02-15 |
Poseida Therapeutics, Inc. |
Chimeric cd8-alpha co-receptor compositions and methods of use
|